Regeneron Pharmaceuticals Investors Alerted to Class Action Lawsuit with Deadline Approaching Soon
Legal Notice for Investors of Regeneron Pharmaceuticals, Inc.
The Gross Law Firm has published an important update for shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding a pending class action lawsuit that could have significant implications for affected investors. If you purchased shares during the specified class period, the deadline to register as a lead plaintiff is approaching fast, set for March 10, 2025.
Class Period and Allegations
The lawsuit relates to transactions occurring between November 2, 2023, and October 30, 2024. During this period, the complaint alleges that Regeneron engaged in misleading actions that distorted the true nature of the company’s operations and sales.
Key allegations include:
1. The company purportedly paid credit card fees to distributors under a condition that they would not increase charges on customers using credit cards for purchasing Eylea, one of Regeneron’s flagship products.
2. These payments reportedly subsidized the prices that customers paid when opting to use credit cards, contributing to a deceptive boost in reported Eylea sales.
3. In this process, Regeneron allegedly provided price concessions that inadvertently favored Eylea, thereby misleadingly inflating the reported Average Selling Price (ASP), constituting a violation of the False Claims Act.
Implications for Affected Investors
The Gross Law Firm encourages all shareholders who acquired REGN shares during the defined period to reach out and explore their rights in the context of the lawsuit. The expression of interest does not obligate investors to be appointed as lead plaintiffs.
Investors who register will benefit from a monitoring service that provides ongoing updates throughout the litigation's lifecycle. This offers shareholders peace of mind, ensuring that they stay informed as the case progresses.
How to Participate
Shareholders are urged not to procrastinate and to register soon to secure their rights. Participation in this case involves no cost or financial obligation and offers a potential avenue to recover losses incurred due to misleading practices.
Registration can be completed online through the Gross Law Firm’s dedicated links:
About The Gross Law Firm
The Gross Law Firm is a well-regarded class action law firm committed to safeguarding the interests of investors who have been impacted by deceitful practices. The firm strives to hold companies accountable for any actions that lead to artificial inflation of their stock for personal gain. Their thorough expertise and commitment to investor rights underscore their mission to uphold responsible corporate conduct.
For additional information or inquiries, investors can contact:
- - The Gross Law Firm
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
Take action today and ensure your voice is heard in this crucial matter affecting all shareholders of Regeneron Pharmaceuticals. The right to seek recovery is one that investors should not ignore as the deadline looms closer.
Conclusion
As the deadline of March 10, 2025 approaches, it is imperative that investors stay proactive regarding their rights and potential claims. This class action lawsuit not only highlights serious allegations against Regeneron Pharmaceuticals but also serves as a stark reminder of the importance of vigilance in the investing landscape. Every shareholder affected has a role to play in seeking accountability and ensuring that their rights are protected.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.